Ellssel Monika, Berlis Ansgar, Naumann Markus, Muthuraman Muthuraman, Ding Hao, Schwarting Sönke, Joachimski Felix, Maurer Christoph J, Bayas Antonios
Department of Neurology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Department of Neuroradiology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Ther Adv Neurol Disord. 2025 Jun 26;18:17562864251345650. doi: 10.1177/17562864251345650. eCollection 2025.
Non-ischemic cerebral enhancing (NICE) lesions are a rare complication following endovascular therapy (EVT) for cerebral aneurysms. Although first described in 2008, data on long-term outcome and treatment response remain limited.
In this study, we investigated the long-term follow-up of patients with NICE lesions, including magnetic resonance imaging (MRI) findings, clinical course, and treatment.
For this single-center ambispective observational study, we enrolled nine patients with NICE lesions after EVT for cerebral aneurysms.
We analyzed patients diagnosed with NICE lesions following EVT between 2008 and 2024 at the University Hospital of Augsburg. Data collection included patients' and procedural characteristics, clinical course, MRI findings, and response to immunotherapies.
We present the long-term follow-up of five patients already published and four additional cases. Nine female patients (mean age at diagnosis 50.67 ± 11.82 (± standard deviation, SD) years) were identified and analyzed with a mean follow-up of 1659.44 ± 1426.87 (SD) days, ranging from 328 to 5223 days (cumulative follow-up of 40.92 patient-years). In total, 112 MRIs were available for evaluation. Eight patients developed symptoms at a mean of 11 ± 13.41 (SD) days post-EVT, one patient remained asymptomatic. New NICE lesions during follow-up were detected in six patients, five patients developed new or increasing symptoms. All patients received glucocorticosteroids with variable duration, six patients required additional immunotherapies. At final follow-up, all patients had a favorable outcome (modified Rankin Scale 0-1), though residual symptoms persisted in four of them.
Hitherto, this study presents the longest follow-up period of patients developing NICE lesions after EVT. NICE lesions may have a highly variable course regarding radiological and clinical characteristics, with potential for both clinical and radiological recurrence years after initial presentation. While immunosuppressive therapy appears effective, optimal treatment regimens and duration have yet to be determined. Our findings underline the importance of regular clinical and MRI controls for individual patient care in this rare condition.
非缺血性脑强化(NICE)病变是脑动脉瘤血管内治疗(EVT)后一种罕见的并发症。尽管于2008年首次被描述,但关于其长期预后和治疗反应的数据仍然有限。
在本研究中,我们调查了NICE病变患者的长期随访情况,包括磁共振成像(MRI)表现、临床病程及治疗情况。
在这项单中心双向观察性研究中,我们纳入了9例脑动脉瘤EVT术后发生NICE病变的患者。
我们分析了2008年至2024年在奥格斯堡大学医院诊断为NICE病变的患者。数据收集包括患者及手术特征、临床病程、MRI表现以及对免疫治疗的反应。
我们展示了5例已发表患者的长期随访情况以及另外4例病例。共识别并分析了9例女性患者(诊断时平均年龄50.67±11.82(±标准差,SD)岁),平均随访时间为1659.44±1426.87(SD)天,范围为328至5223天(累计随访40.92患者年)。总共112次MRI可供评估。8例患者在EVT术后平均11±13.41(SD)天出现症状,1例患者无症状。随访期间6例患者检测到新的NICE病变,5例患者出现新的或加重的症状。所有患者均接受了不同疗程的糖皮质激素治疗,6例患者需要额外的免疫治疗。在末次随访时,所有患者预后良好(改良Rankin量表评分为0 - 1),尽管其中4例仍有残留症状。
迄今为止,本研究呈现了EVT术后发生NICE病变患者最长的随访期。NICE病变在放射学和临床特征方面可能具有高度可变的病程,初次出现后数年可能出现临床和放射学复发。虽然免疫抑制治疗似乎有效,但最佳治疗方案和疗程尚未确定。我们的研究结果强调了在这种罕见情况下,定期进行临床和MRI检查以个体化护理患者的重要性。